Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy + toripalimab versus 9MW2821 + toripalimab as neoadjuvant therapy in upper tract urothelial carcinoma
ChiCTR2600117688Phase 2Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab and bulumtatug fuvedotin in upper tract urothelial carcinoma (UTUC) (3 cohorts), sponsored by Peking University Third Hospital. Primary endpoint: Pathological Complete Response (pCR) rate. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
toripalimabbulumtatug fuvedotin
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on ChiCTR2600117688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117688.